KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Operating Leases (2019 - 2025)

Charles River Laboratories International (CRL) has 7 years of Operating Leases data on record, last reported at $443.2 million in Q3 2025.

  • For Q3 2025, Operating Leases rose 2.39% year-over-year to $443.2 million; the TTM value through Sep 2025 reached $443.2 million, up 2.39%, while the annual FY2024 figure was $483.8 million, 15.4% up from the prior year.
  • Operating Leases reached $443.2 million in Q3 2025 per CRL's latest filing, down from $453.7 million in the prior quarter.
  • Across five years, Operating Leases topped out at $483.8 million in Q4 2024 and bottomed at $253.0 million in Q4 2021.
  • Average Operating Leases over 5 years is $403.3 million, with a median of $418.7 million recorded in 2023.
  • Peak YoY movement for Operating Leases: soared 72.46% in 2022, then fell 3.91% in 2023.
  • A 5-year view of Operating Leases shows it stood at $253.0 million in 2021, then soared by 72.46% to $436.3 million in 2022, then fell by 3.91% to $419.2 million in 2023, then increased by 15.4% to $483.8 million in 2024, then decreased by 8.39% to $443.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $443.2 million in Q3 2025, $453.7 million in Q2 2025, and $475.1 million in Q1 2025.